Advertisement

Current Diabetes Reports

, 18:133 | Cite as

Who Will Win: Induced Pluripotent Stem Cells Versus Embryonic Stem Cells for β Cell Replacement and Diabetes Disease Modeling?

  • Elena F. Jacobson
  • Emmanuel S. Tzanakakis
Immunology, Transplantation, and Regenerative Medicine (L Piemonti and V Sordi, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Immunology, Transplantation, and Regenerative Medicine

Abstract

Purpose of Review

Ever since the reprogramming of human fibroblasts to induced pluripotent stem cells (hiPSCs), scientists have been trying to determine if hiPSCs can give rise to progeny akin to native terminally differentiated cells as human embryonic stem cells (hESCs) do. Many different somatic cell types have been successfully reprogrammed via a variety of methods. In this review, we will discuss recent studies comparing hiPSCs and hESCs and their ability to differentiate to desired cell types as well as explore diabetes disease models.

Recent Findings

Both somatic cell origin and the reprogramming method are important to the epigenetic state of the hiPSCs; however, genetic background contributes the most to differences seen between hiPSCs and hESCs.

Summary

Based on our review of the relevant literature, hiPSCs display differences compared to hESCs, including a higher propensity for specification toward particular cell types based on memory retained from the somatic cell of origin. Moreover, hiPSCs provide a unique opportunity for creating diabetes disease models.

Keywords

Human pluripotent stem cells Diabetes Reprogramming Differentiation Disease models 

Notes

Funding Information

Funding support has been provided by the National Science Foundation (NSF), award CBET-1743367.

Compliance with Ethical Standards

Conflict of Interest

Elena F. Jacobson and Emmanuel S. Tzanakakis declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Jin SM, Kim KW. Is islet transplantation a realistic approach to curing diabetes? Korean J Intern Med. 2017;32(1):62–6.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145–7.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72.CrossRefGoogle Scholar
  4. 4.
    Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917–20.CrossRefPubMedGoogle Scholar
  5. 5.
    Malik N, Rao MS. A review of the methods for human iPSC derivation. Methods Mol Biol. 2013;997:23–33.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hussein SM, Batada NN, Vuoristo S, Ching RW, Autio R, Narva E, et al. Copy number variation and selection during reprogramming to pluripotency. Nature. 2011;471(7336):58–62.CrossRefPubMedGoogle Scholar
  7. 7.
    Nazor KL, Altun G, Lynch C, Tran H, Harness JV, Slavin I, et al. Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives. Cell Stem Cell. 2012;10(5):620–34.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Pick M, Stelzer Y, Bar-Nur O, Mayshar Y, Eden A, Benvenisty N. Clone- and gene-specific aberrations of parental imprinting in human induced pluripotent stem cells. Stem Cells. 2009;27(11):2686–90.CrossRefPubMedGoogle Scholar
  9. 9.
    Mayshar Y, Ben-David U, Lavon N, Biancotti JC, Yakir B, Clark AT, et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell. 2010;7(4):521–31.CrossRefPubMedGoogle Scholar
  10. 10.
    Kim K, Zhao R, Doi A, Ng K, Unternaehrer J, Cahan P, et al. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol. 2011;29(12):1117–9.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Rouhani F, Kumasaka N, de Brito MC, Bradley A, Vallier L, Gaffney D. Genetic background drives transcriptional variation in human induced pluripotent stem cells. PLoS Genet. 2014;10(6):e1004432.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ruiz S, Diep D, Gore A, Panopoulos AD, Montserrat N, Plongthongkum N, et al. Identification of a specific reprogramming-associated epigenetic signature in human induced pluripotent stem cells. PNAS. 2012;109(40):16196–201.CrossRefPubMedGoogle Scholar
  13. 13.
    Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature. 2011;471(7336):68–73.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    •• Choi J, Lee S, Mallard W, Clement K, Tagliazucchi GM, Lim H, et al. A comparison of genetically matched cell lines reveals the equivalence of human iPSCs and ESCs. Nat Biotechnol. 2015;33(11):1173–81 Study used isogenic hESCs and hiPSCs for comparison to determine the role of genetic background on epigenetic differences between hESCs and hiPSCs. CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Mallon BS, Hamilton RS, Kozhich OA, Johnson KR, Fann YC, Rao MS, et al. Comparison of the molecular profiles of hESCs and hiPSCs of isogenic origin. Stem Cell Res. 2014;12(2):376–86.CrossRefPubMedGoogle Scholar
  16. 16.
    Bar-Nur O, Russ HA, Efrat S, Benvenisty N. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell. 2011;9(1):17–23.CrossRefPubMedGoogle Scholar
  17. 17.
    •• Thurner M, Shenhav L, Wesolowska-Andersen A, Bennett AJ, Barrett A, Gloyn AL, et al. Genes Associated with Pancreas Development and Function Maintain Open Chromatin in iPSCs Generated from Human Pancreatic Beta Cells. Stem Cell Rep. 2017;9(5):1395–405 The open chromatin structure (associated with active gene transcription) of β cell-derived hiPSCs compared to fibroblast-originating hiPSCs as they relate to open chromatin structures in human islets was studied.CrossRefGoogle Scholar
  18. 18.
    Drawnel FM, Boccardo S, Prummer M, Delobel F, Graff A, Weber M, et al. Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. Cell Rep. 2014;9(3):810–21.CrossRefPubMedGoogle Scholar
  19. 19.
    Thatava T, Kudva YC, Edukulla R, Squillace K, De Lamo JG, Khan YK, et al. Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells. Mol Ther. 2013;21(1):228–39.CrossRefPubMedGoogle Scholar
  20. 20.
    •• Braverman-Gross C, Nudel N, Ronen D, Beer NL, McCarty MI, Benvenisty N. Derivation and molecular characterization of pancreatic differentiated MODY1-iPSCs. Stem Cell Res. 2018;31:16–26 hiPSCs were derived from a MODY1 (HNF4A transcription factor mutation) patient and differentiated to the pancreatic lineage. It was reported that the HNF4A target gene's differential expression depends on the number of HNF4A binding sites. The effect is more pronounced if the binding sites are closer to the target gene transcription start site and the target gene has fewer binding sites for other transcription factors in its promoter.CrossRefPubMedGoogle Scholar
  21. 21.
    • Teo AK, Lau HH, Valdez IA, Dirice E, Tjora E, Raeder H, et al. Early developmental perturbations in a human stem cell model of MODY5/HNF1B pancreatic hypoplasia. Stem Cell Rep. 2016;6(3):357–67 Human iPSCs were generated from a MODY5 (HFN1B mutation) patient and differentiated to pancreatic cell progenitors. The resulting cells show increased expression of several pancreatic cell transcription factors ( PDX1 , PTF1A , GATA4 , and GATA6 ) and a decrease in PAX6 expression in comparison to the control.CrossRefGoogle Scholar
  22. 22.
    Stanescu DE, Hughes N, Kaplan B, Stanley CA, De Leon DD. Novel presentations of congenital hyperinsulinism due to mutations in the MODY genes: HNF1A and HNF4A. J Clin Endocrinol Metab. 2012;97(10):E2026–30.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    • Vethe H, Bjorlykke Y, Ghila LM, Paulo JA, Scholz H, Gygi SP, et al. Probing the missing mature beta-cell proteomic landscape in differentiating patient iPSC-derived cells. Sci Rep. 2017;7(1):4780 Human iPSCs were produced from a MODY1 patient and successfully differentiated into insulin-positive cells. This suggests that a HNF4A mutation does not prevent expression of insulin genes. The differentiated cells were shown to be immature in comparison to human islets. CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Rezania A, Bruin JE, Arora P, Rubin A, Batushansky I, Asadi A, et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol. 2014;32(11):1121–33.CrossRefPubMedGoogle Scholar
  25. 25.
    Pagliuca FW, Millman JR, Gurtler M, Segel M, Van Dervort A, Ryu JH, et al. Generation of functional human pancreatic beta cells in vitro. Cell. 2014;159(2):428–39.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    • Hosokawa Y, Toyoda T, Fukui K, Baden MY, Funato M, Kondo Y, et al. Insulin-producing cells derived from 'induced pluripotent stem cells' of patients with fulminant type 1 diabetes: vulnerability to cytokine insults and increased expression of apoptosis-related genes. J Diabetes Investig. 2017.  https://doi.org/10.1111/jdi.12727. Human iPSCs were derived from a patient with fulminant type 1 diabetes to better understand β-cell destruction. Differences were observed vs. control hiPSCs in response to cytokines.
  27. 27.
    Shang L, Hua H, Foo K, Martinez H, Watanabe K, Zimmer M, et al. β-cell dysfunction due to increased ER stress in a stem cell model of Wolfram syndrome. Diabetes. 2014;63:923–33.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    La Spada A, Ntai A, Genovese S, Rondinelli M, De Blasio P, Biunno I. Generation of human-induced pluripotent stem cells from Wolfram syndrome type 2 patients bearing the c.103 + 1G>a CISD2 mutation for disease modeling. Stem Cells Dev. 2018;27(4):287–95.CrossRefPubMedGoogle Scholar
  29. 29.
    Maehr R, Chen S, Snitow M, Ludwig T, Yagasaki L, Goland R, et al. Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A. 2009;106(37):15768–73.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kudva YC, Ohmine S, Greder LV, Dutton JR, Armstrong A, De Lamo JG, et al. Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes. Stem Cells Transl Med. 2012;1(6):451–61.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Griscelli F, Ezanno H, Soubeyrand M, Feraud O, Oudrhiri N, Bonnefond A, et al. Generation of an induced pluripotent stem cell (iPSC) line from a patient with maturity-onset diabetes of the young type 3 (MODY3) carrying a hepatocyte nuclear factor 1-alpha (HNF1A) mutation. Stem Cell Res. 2018;29:56–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Teo AK, Windmueller R, Johansson BB, Dirice E, Njolstad PR, Tjora E, et al. Derivation of human induced pluripotent stem cells from patients with maturity onset diabetes of the young. J Biol Chem. 2013;288(8):5353–6.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Siller R, Naumovska E, Mathapati S, Lycke M, Greenhough S, Sullivan GJ. Development of a rapid screen for the endodermal differentiation potential of human pluripotent stem cell lines. Sci Rep. 2016;6:37178.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Nishizawa M, Chonabayashi K, Nomura M, Tanaka A, Nakamura M, Inagaki A, et al. Epigenetic variation between human induced pluripotent stem cell lines is an indicator of differentiation capacity. Cell Stem Cell. 2016;19(3):341–54.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Chemical and Biological EngineeringTufts UniversityMedfordUSA
  2. 2.Clinical and Translational Science InstituteTufts Medical CenterBostonUSA

Personalised recommendations